STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH.

Slides:

Advertisements

Similar presentations

18Feb2009VRBPAC Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Advertisements

Candidate Vaccine Strains and Potency Reagents for Influenza Season

Influenza Vaccine Manufacturing

Candidate Vaccine Strains and Potency Reagents, Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

An Approach to Demonstration of Effectiveness

Vaccines and Related Biological Products

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Timothy Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

A Brief Update of Global Situation and Response to Pandemic Influenza A(H1N1) 2009 Wenqing Zhang MD Global Influenza Programme WHO HQ THE 3rd MEETING OF.

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Immunization in the Time of H1N1 Anne Schuchat, MD Rear Admiral, US Public Health Service Director, National Center for Immunization and Respiratory Diseases.

Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

U.S. Influenza Surveillance Keiji Fukuda Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.

KEY CONCEPT Some viral diseases can be prevented with vaccines.

Influenza Branch Division of Viral and Rickettsial Diseases National Center for Infectious Diseases Centers for Disease Control and Prevention Atlanta,

Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.

Food and Drug Administration

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

The Current Season: A Review of the Influenza Season Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE USPHS INFLUENZA VIRUS VACCINE STRAIN SELECTION

Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.

INFLUENZA UPDATE DEBBYE ROSEN ADULT IMMUNIZATION COORDINATOR CONNECTICUT DEPARTMENT OF PUBLIC HEALTH

Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza.

Influenza Virus Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products.

Influenza H1N1 Introduction. What is Influenza A H1N1?  Influenza virus  Family Orthomyxoviridae  2 important surface proteins  Haemagglutinin (H)

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

Influenza Branch VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA February 16-17, 2005, Bethesda, MD Nancy COX, Ph.D. WHO COLLABORATING.

Vaccines: A Molecular View

Update on Surveillance for Influenza Viruses with Pandemic Potential and Candidate Vaccine Viruses Nancy Cox, PhD CDC.

Seasonal and Pandemic Influenza Research Activities National Vaccine Advisory Committee Meeting September 27, 2006 Barbara L. Mulach, Ph.D. National Institute.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

PROJECT MANAGEMENT Influenza Annual Update Weesp, February Dorine Leyssius.

Lisa Grohskopf, MD, MPH U.S. Influenza Surveillance Season National Center for Immunization & Respiratory Diseases Influenza Division U.S. Food.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Options for Influenza Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological.

DoD Global Influenza Surveillance Program Sentinel Site Surveillance at AFIOH Sequence Analysis And Vaccine Effectiveness Overview Luke T. Daum, PhD, Molecular.

NVAC Influenza Working Group: Preliminary Report Charles Helms, M.D., Ph.D. June 1, 2004.

INFORMATION FOR THE VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE, CEBR, FDA February 27-28, 2007 WHO COLLABORATING CENTER FOR SURVEILLANCE,

Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.

Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.

Copyright © 2017 American Academy of Pediatrics.

Table 4 Results of 3 pairwise comparisons of expanded virus groups, by use of least-squares means differences and the Tukey honestly significant difference.

Copyright © 2017 American Academy of Pediatrics.

KEY CONCEPT Some viral diseases can be prevented with vaccines.

Influenza Vaccines: From Surveillance Through Production to Protection

Professional Organizations

Planning for Pandemic Influenza

KEY CONCEPT Some viral diseases can be prevented with vaccines.

J. -H. Lin, S. -C. Chiu, J. -C. Cheng, H. -W. Chang, K. -L. Hsiao, Y

KEY CONCEPT Some viral diseases can be prevented with vaccines.

KEY CONCEPT Some viral diseases can be prevented with vaccines.

Number of 2019–2020 seasonal influenza vaccine doses for children based on age and previous vaccination history and recommendations for prevention and.

Influenza algorithm for determining recommended 2009–2010 influenza immunization. a Contraindications: please refer to page 7 of the policy statement for.

Presentation transcript:

STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH February 16, 2005

Current VaccineReassortantGrowth A/New Caledonia/20/99 IVR-116 Mod/high Candidate Strains: No new antigenically divergent strains available INFLUENZA A (H1N1) VIRUSES

Current VaccineReassortantGrowth A/Wyoming/03/03 NYMC-X-147 High NYMC-X-149 IVR-134 Candidate Strains: A/Wellington/01/04* RESVIR-20Mod/High IVR-139 Mod/High NYMC-X-155Mod/High * Recommended for Southern hemisphere in the 2005 season INFLUENZA A (H3N2) VIRUSES

A/California/7/04-like Candidate Strains: Egg-isolate ResassortantGrowth in Eggs A/Singapore/37/04IVR-140Mod A/New York/55/04N/A Mod A/California/7/04N/ALow A/Wisconsin/19/04N/A Low A/New York/40/04N/A No/Low A/North Dakota /01/04N/A No/Low A/Washington/01/04 N/ANo/Low INFLUENZA A (H3N2) VIRUSES-Cont.

Laboratories Preparing A/California/7/04-like Candidates 1) Center for Biologics Evaluation and Research - US 2) Centers for Disease Control and Prevention - US 3) New York Medical College - US 4) National Institute for Biological Standards and Control - UK 5) CSL- Australia 6) National Institute Infectious Diseases - Japan INFLUENZA A (H3N2) VIRUSES-Cont.

Current vaccines: Growth (B/Shanghai/361/02-like =Yamagata lineage ) B/Shanghai/361/02Moderate B/Jilin/20/03Moderate B/Jiangsu/10/03 Moderate Candidate Strains: No new antigenically divergent strains currently under evaluation INFLUENZA B VIRUSES

Reagents Currently Available for Type A: H1N1: A/New Caledonia/20/99 H3N2: A/Wyoming/03/03 If new strains are chosen, reagents will be available in May at the earliest. POTENCY REAGENTS

Reagents Currently Available for Type B: B/Shanghai/361/02-like (Yamagata lineage): B/Jiangsu/10/03 B/Hong Kong/330/01-like (Victoria lineage): B/Hong Kong/330/01 B/Hong Kong/1434/02 B/Shandong/07/97 If new strains are chosen, reagents will be available in May at the earliest. POTENCY REAGENTS